Nambling, Glyden B.
HRN: 27-33-82 Sex: FemalePatient Encounter
AMS Audit List
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
06/16/2025
CEFUROXIME 750MG (VIAL)
06/16/2025
06/22/2025
IV
750mg
Q8h
UTI
Checking Initial Appropriateness